Australian students recreate Martin Shkreli price-hike drug in school lab; Guardian, 11/30/16

Melissa Davey, Guardian; Australian students recreate Martin Shkreli price-hike drug in school lab:

"He said the open nature of the project demystified science and revealed the number of roadblocks the students had faced in coming up with the final product, which involved three complicated chemical steps.

“With science results you can be presented with a polished finished product that hides the false steps along the way,” he said. “The students’ real-time diary highlights their whole process, and is a very transparent way of doing things.”...

He said unfortunately the students would not be able to sell their drug to the US market. While the drug can be bought in Australia for about A$13 for a packet of 50, there are a number of complicated legal roadblocks in the way of producing and selling it in the US.

“Turing has the exclusive rights to sell it, even though the drug is no longer under patent,” Todd said. “The ridiculousness of this legal loophole means if we wanted to launch it as drug in the US we’d have to go through a whole new clinical trial because we would have to compare the Sydney Grammar stuff with the officially sanctioned stuff, and Turing would have to give us the drug to allow those comparisons to be made."

The Strange Case of Off-Patent Drug Price Gougers; Bloomberg, 9/9/16

Justin Fox, Bloomberg; The Strange Case of Off-Patent Drug Price Gougers:

"There’s a conflict at the heart of pharmaceutical pricing in the U.S.: On the one hand, it’s in the public’s interest for pharma companies to get a good return on the huge investments they often make in developing new drugs. On the other, it’s in the public’s interest to be able to afford those drugs.

We try to resolve this by granting companies temporary monopolies (aka patents) on the drugs they develop -- letting them effectively set the price unilaterally -- but then allowing competition from generic substitutes once the patents expire...

What’s going on, basically, is that a new breed of pharmaceutical company has emerged (Valeant is, or at least was, the archetype) that doesn’t develop drugs but identifies business opportunities in existing drugs --many of them with expired patents -- that the previous owners were too lazy or timid or decent to fully exploit. So they acquire them, and jack up the prices."